16. Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. *J Biol Chem* 1951;193:265-275
17. Parris WCV, Kambam JR, Naukam RJ, Sastry BVR. Immunoreactive-substance P is decreased in saliva of patients with chronic back syndromes. *Anesth Analg* 1990;70:63-67
18. Wharton J, Polak JM, McGregor GP, et al. The distribution of substance P-like immunoreactive nerves in the guinea pig heart. *Neuroscience* 98;6:2193-2204
19. Kambam JR, Merrill W, Parris W, et al. Substance P, acetylcholinesterase, and beta-endorphin levels in the plasma and pericardial fluid of patients with and without angina pectoris. *J Lab Clin Med* 1991 (in press)
20. Theodorsson-Norheim E, Norheim I, Oberg K, Brodin E. Neuropeptide K: a major tachykinin in plasma and tumor tissues from carcinoid patients. *Biochem Biophys Res Commun* 1985;131:7783
21. Parris WCV, Kambam JR, Naukam, RJ, et al. The effect of somatostatin on plasma substance P (SP) in carcinoid syndrome. *Regul Pept* 1988;22:142

CORRECTION

An error appeared in the abstract "Evaluation of the New Engstrom Elsa Anesthetic Vaporizing Principle," which appeared in the January issue of the *Journal* (Rolly G, Versichelen L, *J Clin Monit* 1991;7:128). In the line "This is a safety procedure built into the program, which allows only a maximal electrically calculated output of 36.1%," 36.1% should read 36.L%. The *Journal* apologizes for this error.